Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/PO.20.00272 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis.
Discov Oncol
March 2025
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Background: Lung cancer is one of the most common malignant tumors worldwide. This article aims to review the current research status and trends in PD-1/PD-L1 inhibitor immunotherapy.
Method: On the basis of the Web of Science Core Collection database, literature on PD-1/PD-L1 inhibitor immunotherapy in lung cancer patients was searched and analyzed for all years up to August 5, 2023.
Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease.
Front Immunol
February 2025
R&D Department, OncoAtlas LLC, Moscow, Russia.
Microsatellite instability (MSI) is a widely studied molecular signature, which is associated with long-term benefit in patients treated with immune checkpoint inhibitor therapy. This approach has been proven to be effective in the treatment of patients with MSI-positive colorectal cancer (CRC). Analysis of serial liquid biopsy samples allows to detect changes in the tumor in response to therapy.
View Article and Find Full Text PDFTribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepatocellular Carcinoma.
Adv Sci (Weinh)
February 2025
Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
Rapid development of resistance to sorafenib and subsequent hyperprogression in patients with advanced hepatocellular carcinoma (HCC) pose significant challenges, with the underlying mechanisms still largely unknown. Herein, sorafenib-induced TRIB3 is identified as a liver-specific determinant driving secondary resistance to sorafenib by facilitating the accumulation of protumorigenic neutrophils within tumors. Mechanistically, TRIB3, triggered by the sorafenib-elicited ROS-ER stress axis, operates in an NF-κB-dependent manner to upregulate CXCR1/2 ligands, subsequently promoting neutrophil recruitment into tumors.
View Article and Find Full Text PDFPseudo-hyperprogression of Malignant Pleural Mesothelioma Treated with Nivolumab: A Case Report.
Intern Med
February 2025
Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Currently, immune checkpoint inhibitors (ICIs) are the standard treatment for malignant pleural mesothelioma (MPM). The characteristic responses to ICI treatment include pseudoprogression (PP) and hyperprogressive disease (HPD), which require attention. Reports on PP of MPM are rare.
View Article and Find Full Text PDFHyperprogression of brain metastases following initiation of immune checkpoint inhibitors.
J Neurooncol
February 2025
Department of Neurosurgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, Zuid-Holland, The Netherlands.
Purpose: Immune checkpoint inhibitors (ICI) are increasingly being administered to cancer patients, including those with brain metastases (BMs). However, in a subset of cancer patients, ICI have shown to paradoxically accelerate tumor growth. This phenomenon is known as hyperprogressive disease (HPD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!